ProCE Banner Activity

New Agents and Evolving Strategies in Castration-Sensitive Prostate Cancer (CSPC)

Clinical Thought
Expert commentary by Atish Choudhury, MD, PhD, on key takeaways from a live symposium on new and evolving androgen-deprivation therapies and treatment approaches for patients with castration-sensitive prostate cancer, including data from the 2022 ASCO Genitourinary Cancers Symposium.

Released: March 30, 2022

Expiration: March 29, 2023

No longer available for credit.

Share

Faculty

Atish Choudhury

Atish Choudhury, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Senior Physician
Medical Oncology
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Myovant Sciences Inc

Pfizer, Inc.

Faculty Disclosure

Primary Author

Atish Choudhury, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Senior Physician
Medical Oncology
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Atish Choudhury, MD, PhD, has disclosed that he has received consulting fees from Astellas, AstraZeneca, Bayer, Blue Earth, and Lilly.